))
Investment Strategies in Phage Therapy with Dr. Richard Alm at CARB-X
Manage episode 315364571 series 3287704
Conteúdo fornecido por Steven Yang. Todo o conteúdo do podcast, incluindo episódios, gráficos e descrições de podcast, é carregado e fornecido diretamente por Steven Yang ou por seu parceiro de plataforma de podcast. Se você acredita que alguém está usando seu trabalho protegido por direitos autorais sem sua permissão, siga o processo descrito aqui https://pt.player.fm/legal.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator(CARB-X) is one global nonprofit partnership that manages a large portfolio of early stage companies to do the job as described by its name. In this episode, we are happy to have its chief scientist Dr. Richard Alm to help us paint a broad picture of the antimicrobial landscape and discuss their investment strategies related to phage therapy. The global biotech is a $800B dollar market this year, with a >15% CAGR, what can we do to promote the scientific understanding of phage and phage therapy in this capital driven economy?
Find out more about CARB-X at their website: https://carb-x.org
18 episódios
Compartilhar
